Corvalol-MFF (CORVALOL-MFF)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbspdrops for oral administration
Composition:

Active substances:

Phenobarbital

1.96 g

Ethyl bromoisovaleric acid

2.15 g

(Ethyl ester of α-bromoisovaleric acid)

Excipients:

up to 100.00 g

Sodium hydroxide

0.12 g

Peppermint oil

0.15 g

Ethanol (ethyl alcohol) 95%

51.08 g

Purified water

44.54 g
Description:

A clear, colorless liquid with a specific aromatic odor.

Pharmacotherapeutic group:Sedative remedy
ATX: & nbsp
  • Other sleeping pills and sedatives
    • Pharmacodynamics:

    Combined drug, the effect of which is due to the properties of its constituent substances. Has a sedative and spasmolytic effect. Facilitates the onset of natural sleep.

    Ethyl ether α-bromoisovaleric acid has a sedative effect (similar to the valerian effect) and an antispasmodic effect, which is caused by stimulation of the predominantly oral and nasopharyngeal receptors, a decrease in reflex excitability in the central parts of the nervous system, and an increase in inhibition in neurons of the cortex and subcortical structures of the brain, as well as a decrease in the activity of the central vasomotor centers and direct local antispasmodic effect on smooth muscles.

    Phenobarbital strengthens the sedative effect of other components, helps to reduce excitation of the central nervous system (CNS) and facilitates the onset of sleep.

    Indications:

    Corvalol-MPF is prescribed as a symptomatic (soothing and vasodilating) remedy for functional disorders of the cardiovascular system, neurosis-like conditions, accompanied by increased irritability, with disturbed sleep, tachycardia, arousal state with pronounced vegetative manifestations; as spasmolytic agent - with intestinal spasms.

    Contraindications:

    Hypersensitivity to the components of the drug; marked impairment of renal and / or liver function; lactation period (if it is necessary to use during breastfeeding, decide whether to stop breastfeeding), pregnancy, alcoholism, craniocerebral trauma or brain disease; children's age up to 3 years.

    Carefully:Child age from 3 years.
    Dosing and Administration:

    The dose is set individually.

    Inside, before eating, pre-dissolved in a small amount (30-50 ml) of water.

    Single dose in adults is 30 drops, if necessary (for example, with tachycardia) can be increased to 40-50 drops. Multiplicity of admission in adults - 2-3 times a day.

    Children from 3 years old Apply 1 drop per year for a child at a time per day.

    The need for a repeated dose is determined by the doctor depending on the clinical picture of the disease.

    Duration of the drug is determined by the doctor individually.

    Side effects:

    Drowsiness, dizziness, slow heart rate, decreased ability to concentrate, allergic reactions.

    With long-term admission - the phenomenon of bromism, addiction, drug dependence, withdrawal syndrome.

    Overdose:

    Symptoms: depression of the central nervous system, nystagmus, ataxia, lowering of arterial pressure, violations of the blood formula, excitation, chronic intoxication with bromine (depression, apathy, rhinitis, conjunctivitis, hemorrhagic diathesis, movement coordination disorders).

    Treatment: symptomatic; at oppression of the central nervous system - caffeine, nikethamide.

    Interaction:

    Drugs that depress the central nervous system, enhance the effect of the drug.

    Phenobarbital (inductor of microsomal oxidation) can reduce the effectiveness of drugs metabolized in the liver (including coumarin derivatives, griseofulvin, glucocorticosteroids, oral contraceptives); strengthens the action of local anesthetic, analgesic and hypnotic drugs.

    Effect on the ability to drive transp. cf. and fur:The preparation contains 58% by volume of ethanol and phenobarbital, therefore, patients taking Corvalol-MFF should refrain from driving vehicles and practicing other potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions.
    Form release / dosage:

    Drops for oral administration.

    Packaging:

    For 15 ml, 25 ml and 50 ml in bottles-droppers of orange glass, sealed with stoppers-droppers polymer and caps polymeric screwed or stoppers-droppers and caps screwed; on 15 ml, 25 ml and 50 ml in bottles-droppers glass with a screw mouth from a brown glass, ukuporennye a cap-dropper.

    Each vial-dropper along with the instruction for use is placed in a pack of cardboard.

    Packing for hospitals

    For 17 kg in a glass bottle, sealed with polymeric screw caps with polyethylene gaskets.

    Each bottle is placed in a polyethylene drum.

    Storage conditions:

    Store in a dark place at a temperature of no higher than 20 ° C.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    Do not use after expiry date.

    Terms of leave from pharmacies:Without recipe
    Registration number:P N000438 / 01
    Date of registration:13.05.2009 / 02.07.2013
    Expiration Date:Unlimited
    The owner of the registration certificate:MOSCOW PHARMACEUTICAL FACTORY, CJSC MOSCOW PHARMACEUTICAL FACTORY, CJSC Russia
    Manufacturer: & nbsp
    Representation: & nbspMOSCOW PHARMACEUTICAL FACTORY MOSCOW PHARMACEUTICAL FACTORY Russia
    Information update date: & nbsp18.01.2018
    Illustrated instructions
      Instructions
      Up